Bienvenue à l’Eular 2022 !
Bienvenue à l'Eular 2022 !
Site professionnel spécialisé en Rhumatologie
OP0185. Unizony S, Matza M, Jarvie A et al. Tocilizumab in combination with 8 weeks of prednisone for giant cell arteritis. Eular 2022.
OP0019. Van des Heijde D, Baraliakos X, Dougados M et al. Bimekizumab in patients with active ankylosing spondylitis: 24-week efficacy & safety from BE MOBILE 2, a phase 3, multicentre,…
OP0025. Rahman P, Mease PJ, Deodhar A et al. Factors associated with fatigue and its improvement – a principal component analysis of patients with active psoriatic arthritis from guselkumab phase…
OP0027. Kristensen LE, Strober B, Poddubnyy D et al. Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and…
OP0028. Snoeck Henkemans S, De Jong P, Luime J et al. Early achievement of minimal disease activity in psoriatic arthritis is associated with long-term improvements in quality of life. Eular…
P0058. Østergaard M, Van Vollenhoven R, Rudin A et al. Certolizumab-pegol, abatacept, tocilizumab or active conventional therapy in early rheumatoid arthritis: clinical and radiographic 48-weeks results of the investigator-initiated randomized…
OP0066. Caillet-Portillo D, Puéchal X, Degboe Y et al. Impact of diagnosis and treatment of tropheryma whipplei infection in patients with pre-existing chronic inflammatory rheumatic diseases: data from the national…
OP0059. Antovic A, Vedder D, Rudin A et al. Profound anticoagulant effects of initial antirheumatic treatments in early rheumatoid arthritis patients: a NORD-STAR spin-off study. Eular 2022.
OP0018. Proft F, Muche B, Rios Rodriguez V et al. Comparison of the effect of treatment with NSAIDS added to anti-TNF therapy versus anti-TNF therapy alone on progression of structural…
OP0257. Cordtz R, Askling J, Delcoigne B et al. Risk of haematological malignancy in patients with psoriatic arthritis, overall and in relation to TNF inhibitors - a Nordic cohort study.…
OP0183. Fernández-Fernández E, Monjo I, Peiteado D et al. Validity of the Eular recommendations on the use of ultrasound in the diagnosis of giant cell arteritis. Eular 2022. OP0184. de…
OP0017. Landevé RBM, Poddubnyy D, Rahman P et al. Recapture rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomized placebo-controlled…
OP0182. Wenhoff N, Schmidt WA, Bergner R et al. Secukinumab in giant cell arteritis: the randomised, parallel-group, double-blind, placebo-controlled, multicentre phase 2 TitAIN trial. <strong>Figure 1 - Diagramme Kaplan-Meier du…
